A-08 Applying the 2021 CCS Dyslipidemia Guidelines in Clinical Practice

George Thanassoulis, Canada

Director, Preventive and Genomic Cardiology
McGill University Health Center
McGill University

Questions Submitted

  • I have used other Framingham Risk calculators, and now am using PEER Simplified Cardiovascular Decision Aid which seems to give a higher risk score than most calculators. Why the difference in scores? Which should we use? I remember reading in the past that Framingham Risk tends to over estimate risk, and if PEER gives a higher risk, is it really correct to use it? Your thoughts and advice are appreciated.

  • What is your approach to young women with complications of pregnancy. When do you screen, what are the thresholds for treatment-9assuming lifestyle already addressed), how high do you go with statin doses Thank you Sherry Luger

Objectives

At the conclusion of this session, participants will be able to:

 

•Recognize the major changes in the new guidelines and how they impact on the care of patients with dyslipidemia

•Apply the recent 2021 dyslipidemia guidelines to the management of patients with common lipid disorders in primary care

•Integrate the use of apolipoproteinB,  non-HDL-C amd lipoprotein(a) into their practice

If you have any questions, please consult our Help Desk.
© 2024 McGill Family Physician Refresher Course